In a mouse model of RA, baricitinib decreased the activity of microglia in the area postrema brain region with inhibition of STAT3 phosphorylation and improvement in behavioral outcomes such as food intake [55]. This evidence concerns the gene STAT3 and rheumatoid arthritis.